Research graph
References from PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2024.03.027 · 2024 · External reference
Prostate cancer risk stratification with magnetic resonance imaging
10.1016/j.urolonc.2016.03.001 · 2016 · External reference
Risk stratification and artificial intelligence in early magnetic resonance imaging-based detection of prostate cancer
10.1016/j.euf.2021.11.005 · 2022 · External reference
Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2
10.1016/j.eururo.2019.02.033 · 2019 · External reference
Risk stratification of prostate cancer according to PI-RADS® version 2 categories: meta-analysis for prospective studies
10.1097/ju.0000000000001306 · 2020 · External reference
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2025.12.009 · 2026 · External reference
Best current practice and research priorities in active surveillance for prostate cancer-a report of a movember international consensus meeting
10.1016/j.euo.2023.01.003 · 2023 · External reference
Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy
10.1016/j.eururo.2021.12.007 · 2022 · External reference
Clinical application of the prostate cancer radiological estimation of change in sequential evaluation score for reporting magnetic resonance imaging in men on active surveillance for prostate cancer
10.1016/j.euros.2023.08.006 · 2023 · External reference
PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer
10.1016/j.eururo.2024.03.014 · 2024 · External reference
The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review
10.2214/ajr.23.29518 · 2023 · External reference
Role of MRI in low-risk prostate cancer: finding the wolf in sheep’s clothing or the sheep in wolf’s clothing?
10.1097/mou.0000000000000397 · 2017 · External reference
Prostate cancer radiological estimation of change in sequential evaluation (PRECISE) magnetic resonance imaging scoring to predict clinical outcomes in active surveillance for grade group 1 prostate cancer
10.1016/j.urology.2023.07.019 · 2023 · External reference
Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer
10.1001/jamaoncol.2024.5497 · 2025 · External reference
Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial
10.1001/jama.2025.13722 · 2025 · External reference
Bi-parametric prostate MRI with a recall system for contrast enhanced imaging: improving accessibility while maintaining quality
10.1016/j.ejrad.2023.111186 · 2023 · External reference
The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma
10.1097/pas.0000000000001497 · 2020 · External reference
The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction
10.1016/j.juro.2017.03.130 · 2017 · External reference
Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
10.1111/bju.15277 · 2021 · External reference
PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml
10.1038/s41598-024-57337-y · 2024 · External reference
Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer
10.1007/s00261-022-03592-4 · 2022 · External reference
Genomic and phenotypic heterogeneity in prostate cancer
10.1038/s41585-020-00400-w · 2021 · External reference
Prospective PI-RADS v2.1 atypical benign prostatic hyperplasia nodules with marked restricted diffusion: detection of clinically significant prostate cancer on multiparametric MRI
10.2214/ajr.20.24370 · 2021 · External reference
Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI
10.1007/s00330-017-4775-2 · 2017 · External reference
Differentiation of prostatitis and prostate cancer using the Prostate Imaging-Reporting and Data System (PI-RADS)
10.1016/j.ejrad.2016.04.014 · 2016 · External reference
Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T
10.1148/radiol.12111683 · 2013 · External reference
MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance
10.1007/s00330-020-07336-0 · 2021 · External reference
MRI-derived PRECISE score for predicting pathologically-confirmed progression in prostate cancer patients on active surveillance
2024 · External reference
